TO THE EDITOR
Minimal residual disease (MRD) quantified by immunoglobulin and/or T-cell receptor (Ig/TCR) genes rearrangements real-time quantitative PCR (RQ-PCR) is used for the risk stratification in some of the modern treatment protocols for childhood acute lymphoblastic leukaemia. This accurate and almost generally applicable approach is also laborious and costly. Moreover, in a minority of the patients, a suitable marker (Ig/TCR rearrangement adequately sensitive and specific) cannot be identified, thus precluding proper risk stratification. TEL/AML1 fusion gene -found in approximately 25% of childhood B-cell precursor acute lymphoblastic leukaemias (ALL) -is a tempting target for the MRD monitoring using reverse transcriptase RQ-PCR (RQ-RT-PCR). Its use overcomes the need for the individual design and optimisation of RQ-PCR systems, thus lowering both the costs and laboriousness. Our recent study already clearly demonstrated that slower clearance of TEL/AML1 fusion transcript measured by RQ-RT-PCR predicted relapse.
1 If proven to correlate with MRD dynamics assessed by Ig/TCR RQ-PCR, this mRNA-based approach could complement the latter technique in MRD detection in childhood ALL.
Previous reports trying to show such correlation suffered from various limitations; in general, low numbers of samples were studied (particularly those with MRD detectable by at least one target: n ¼ 6, 2 n ¼ 13 3 and n ¼ 17, 4 respectively). The inadequate sensitivity of TEL/AML1-targeted RQ-RT-PCR 4 and some of the Ig/TCR RQ-PCR systems used 2 might have also influenced the analyses. De Haas et al used only a limited spectrum of Ig/TCR targets (complete Ig heavy chain and TCR delta rearrangements), and only one sample was analysed by two independent Ig/TCR targets, 3 thus not reflecting the real situation in MRD detection. In two of the reports, methods other than RQ-PCR were partially used for target quantitation -competitive PCR 2 and dot-blot approach, 4 respectively. In our recent study, we adhered to the very strict criteria set for Ig/TCR RQ-PCR by the European Study Group on MRD in ALL.
5 These apply to the number of targets (two independent rearrangements for each patient), specificity (six independent negative polyclonal controls in each reaction), sensitivity (at least 10 À4 ) and the rules for calculation of the numerical MRD values. We analysed a total of 117 follow-up bone marrow samples from 28 TEL/AML1-positive patients -20 newly diagnosed (all treated according to ALL IC-BFM 2002 protocol) and eight relapsed (ALL-REZ BFM 2002).
Both methods we compare here were described previously.
1,5-8 All but three patients were investigated by two independent Ig/TCR targets; the sensitivity was better than 10 À4 for 48/53 targets and 5 Â 10 À4 for 5/53 targets. Figure 1 shows the correlation between TEL/AML1 and the Ig/TCR-based method (1a) and between two independent Ig/TCR targets (1b). Although the correlation between TEL/AML1 and Ig/TCR did not reach the excellence of the correlation between two Ig/ TCR targets (R 2 ¼ 0.903 and 0.955, respectively), only 8/117 (o7%) samples differed by more than 1 log. This result supports our previous findings that normalised TEL/AML1 expression (TEL/AML1:housekeeping gene ratio) in surviving leukaemic blasts is stable, influenced neither by the cytostatic treatment 1 nor by the sampling-to-processing time within first 48 h (our unpublished data).
From the results of this prospective study (the largest published so far), we conclude that TEL/AML1 RQ-RT-PCR can conveniently complement MRD analysis for the protocol-required risk stratification in childhood ALL if the second Ig/TCR target is not available or not adequately sensitive/ specific. There is virtually no risk of false-positive result. However, as an underestimation of MRD level by TEL/AML1 RQ-RT-PCR remains conceivable in a small percentage of samples (B5%), TEL/AML1 should be used as a second-choice target only and always in a combination with Ig/TCR-based technique.
Figure 1
Comparison between two targets for MRD monitoring. (a) Comparison of the DNA-based (Ig/TCR) and RNA-based (TEL/AML1) approach. In agreement with ESG-MRD-ALL directions, the higher Ig/TCR value of two available targets was used for comparison. In total, 117 samples were analysed by both methods. Majority of samples (64/117) were positive in at least one system. Area between the lines shows theoretical optimal correlation with o1 log difference between both methods. Only eight samples (o7%) lie outside this area. (b) Comparison of two independent Ig/TCR targets for 96/117 samples analysed in this study. } -patients on frontline treatment; ' -relapsed patients; R 2 ¼ correlation coefficient. For the mathematical analysis, positive samples with MRD values below the quantitative range (otherwise referred as 'positive' only) were set numerically.
